Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Broderick

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Thoracic Cancer|October 15, 2021
Trimodality therapy for esophageal cancer: The role of surgical and radiation treatment parameters in the development of anastomotic complicationsSalem Alfaifi, Robert Chu, Xuan Hui, et al.
Plos One|May 10, 2007
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4Jenifer L Marks, Michael D McLellan, Maureen F Zakowski, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2007
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibJames Bean, Cameron Brennan, Jin-Yuan Shih, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung CancerPatrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.
Cancers|November 9, 2024
Fecal Microbiome Composition Correlates with Pathologic Complete Response in Patients with Operable Esophageal Cancer Treated with Combined Chemoradiotherapy and ImmunotherapyFyza Y Shaikh, Seoho Lee, James R White, et al.
Journal for Immunotherapy of Cancer|September 15, 2020
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancerJoshua E Reuss, Valsamo Anagnostou, Tricia R Cottrell, et al.
Nature Medicine|March 20, 2024
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analysesRonan J Kelly, Blair V Landon, Ali H Zaidi, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery CommitteeBrian Gastman, Piyush K Agarwal, Adam Berger, et al.
The New England Journal of Medicine|April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Kellie N Smith, et al.
Cardiovascular Engineering and Technology|September 12, 2018
Real-World Variability in the Prediction of Intracranial Aneurysm Wall Shear Stress: The 2015 International Aneurysm CFD ChallengeKristian Valen-Sendstad, Aslak W Bergersen, Yuji Shimogonya, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Thoracic Cancer|October 15, 2021
Trimodality therapy for esophageal cancer: The role of surgical and radiation treatment parameters in the development of anastomotic complicationsSalem Alfaifi, Robert Chu, Xuan Hui, et al.
Plos One|May 10, 2007
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4Jenifer L Marks, Michael D McLellan, Maureen F Zakowski, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 21, 2007
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibJames Bean, Cameron Brennan, Jin-Yuan Shih, et al.
The New England Journal of Medicine|June 2, 2025
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung CancerPatrick M Forde, Jonathan D Spicer, Mariano Provencio, et al.
Cancers|November 9, 2024
Fecal Microbiome Composition Correlates with Pathologic Complete Response in Patients with Operable Esophageal Cancer Treated with Combined Chemoradiotherapy and ImmunotherapyFyza Y Shaikh, Seoho Lee, James R White, et al.
Journal for Immunotherapy of Cancer|September 15, 2020
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancerJoshua E Reuss, Valsamo Anagnostou, Tricia R Cottrell, et al.
Nature Medicine|March 20, 2024
Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analysesRonan J Kelly, Blair V Landon, Ali H Zaidi, et al.
Journal for Immunotherapy of Cancer|November 17, 2020
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery CommitteeBrian Gastman, Piyush K Agarwal, Adam Berger, et al.
The New England Journal of Medicine|April 17, 2018
Neoadjuvant PD-1 Blockade in Resectable Lung CancerPatrick M Forde, Jamie E Chaft, Kellie N Smith, et al.
Cardiovascular Engineering and Technology|September 12, 2018
Real-World Variability in the Prediction of Intracranial Aneurysm Wall Shear Stress: The 2015 International Aneurysm CFD ChallengeKristian Valen-Sendstad, Aslak W Bergersen, Yuji Shimogonya, et al.
Pageof 5